Lake Street analyst Thomas Flaten raised the firm’s price target on Personalis (PSNL) to $11 from $9 and keeps a Buy rating on the shares after the company reported Q3 revenue ahead of the guided range, the firm’s estimate and consensus. While noting that Personalis lowered 2025 revenue guidance to reflect macro headwinds in the biopharma business, the firm argues that the key driver of future revenue growth and share price appreciation will be reimbursement.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL: